---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-001958"
form_type: "8-K"
ticker: "PDSB"
cik: "0001472091"
company_name: "PDS Biotechnology Corp"
filed_at: "2026-01-22T23:59:59+00:00"
generated_at: "2026-05-16T08:44:47.141144+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# PDS Biotech receives U.S. patent allowance for PDS0101 with 20-year market protection

## Summary
- U.S. Patent Office issued Notice of Allowance for PDS0101 (Application 16/210,750) covering cationic lipid compositions.
- New patent plus biologics exclusivity expected to provide ~20 years of market protection for PDS0101.
- PDS0101 is in Phase 3 VERSATILE-003 trial for HPV16-positive head and neck cancers.
- Company submitted FDA protocol amendment proposing PFS as primary endpoint for potential accelerated approval.
- IP estate includes granted patents in U.S., Europe, Japan, China, Australia, Canada, Israel, Mexico, and Hong Kong.

## SEC filing metadata
- accession: 0001140361-26-001958
- form_type: 8-K
- ticker: PDSB
- cik: 0001472091
- company_name: PDS Biotechnology Corp
- filed_at: 2026-01-22T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1472091/000114036126001958/0001140361-26-001958-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1472091/000114036126001958/ef20063617_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-001958
- JSON: https://secwatch.observer/filing/0001140361-26-001958.json
- Plain text: https://secwatch.observer/filing/0001140361-26-001958.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.